Quarter-Century Bibliometric Analysis Charts Major Shifts in Solid Tumor Immunotherapy Research
A study tracking 25 years of publication data maps how the clinical and academic focus has transitioned toward neoadjuvant and combination strategies.
Key takeaways
- A bibliometric analysis of 54,546 documents shows immunotherapy research transitioned from the Cytokine Era (2000-2010) to the Checkpoint Revolution (2011-2019) and recently to the Tumor Microenvironment and Neoadjuvant Therapy (2020-2025).
- While China has surpassed the United States in total publication volume, the United States maintains greater per-article citation counts and deeper integration in global networks.
- Research has structurally transitioned from evaluating monotherapy in metastatic settings to studying combinatorial and perioperative strategies in early-stage disease.
- Current translational research shows a strong academic focus on overcoming resistance mechanisms in "cold" tumors by combining and sequencing immunotherapies with antibody-drug conjugates.
Cancer immunotherapy has evolved from an experimental niche to become the established fourth pillar of oncological care. While the clinical success of checkpoint inhibitors is widely documented, understanding how the broader research landscape has evolved over time requires analyzing decades of scientific literature.
To map this trajectory, a bibliometric study published in July 2026 in the International Journal of Medical Sciences analyzed 54,546 documents published between January 1, 2000, and December 31, 2025. Using data from the Web of Science Core Collection and cross-comparing findings with a high-impact Scopus subset, researchers visualized how the scientific focus has shifted geopolitically, conceptually, and structurally. The final data retrieval for the analysis was conducted on January 1, 2026.
What Happened
The research team utilized advanced network visualization techniques via VOSviewer and Biblioshiny to identify spatiotemporal trends in the literature. The analysis of 54,546 documents revealed a rapid and sustained expansion in publication volume. Chronologically, this descriptive trend aligns with major clinical milestones, such as the 2011 FDA approval of ipilimumab.
Geopolitically, the study identified a distinctive divergence between leading research nations. While China has surpassed the United States in total publication volume, the United States maintains higher integration in global collaboration networks and greater per-article citation counts.
What The Evidence Shows
Network analysis visualized a decisive conceptual evolution across three distinct periods:
The Cytokine Era (2000-2010)
The Checkpoint Revolution (2011-2019)
Recent trends (2020-2025), which indicate a clear shift in research toward the "Tumor Microenvironment" and "Neoadjuvant Therapy"
Neoadjuvant therapy has emerged as a predominant focus of recent translational research. Structurally, the academic literature shows a transition from evaluating monotherapies in metastatic settings to studying combinatorial and perioperative strategies in early-stage disease. Additionally, the study noted a growing academic focus on overcoming resistance mechanisms in "cold" tumors, reflecting strong translational interest in combining and sequencing immunotherapies with next-generation modalities, such as antibody-drug conjugates.
What We Don't Know Yet
The primary methodological limitation of this study is its title-restricted search strategy. While searching only titles ensures high clinical specificity, it inherently reduces search sensitivity. Consequently, this approach potentially excluded relevant studies that were published with non-descriptive titles.
What Comes Next
The published study does not report specific plans or next steps for the researchers or sponsors. Unanswered questions remain regarding how future clinical applications will combine and sequence immunotherapies with next-generation modalities to overcome resistance mechanisms in "cold" tumors.
What This Means
This analysis demonstrates that the structural focus of solid tumor immunotherapy is moving toward early-stage cancer and combination approaches. Rather than relying on single-agent therapies in advanced settings, translational medicine is increasingly focused on perioperative strategies and combining immunotherapies with newer modalities like antibody-drug conjugates to overcome resistance mechanisms in "cold" tumors.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42694880/
Questions readers ask
- How has solid tumor immunotherapy research evolved since 2000?
- Research has transitioned through three main phases: the Cytokine Era (2000-2010), the Checkpoint Revolution (2011-2019), and a recent shift toward the Tumor Microenvironment and Neoadjuvant Therapy (2020-2025).
- How do China and the United States compare in immunotherapy publications?
- China has surpassed the United States in total solid tumor immunotherapy publication volume. However, the United States maintains higher integration in global collaboration networks and greater per-article citation counts.
- What are the latest clinical focuses in solid tumor immunotherapy research?
- Recent research focuses on perioperative and combinatorial strategies in early-stage disease rather than monotherapy in metastatic settings. There is also growing translational interest in combining immunotherapies with next-generation modalities like antibody-drug conjugates to overcome resistance in "cold" tumors.
What this means
This analysis demonstrates that the structural focus of solid tumor immunotherapy is moving toward early-stage cancer and combination approaches. Rather than relying on single-agent therapies in advanced settings, translational medicine is increasingly focused on perioperative strategies and combining immunotherapies with newer modalities like antibody-drug conjugates to overcome resistance mechanisms in "cold" tumors.
Limitations and uncertainties
- The primary methodological limitation of this study is its title-restricted search strategy. While searching only titles ensures high clinical specificity, it inherently reduces search sensitivity. Consequently, this approach potentially excluded relevant studies that were published with non-descriptive titles.
